Medivolve Inc. (MEDVF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.33 Million CAD | -0.82% |
| 2022 | 18.49 Million CAD | -55.43% |
| 2021 | 41.48 Million CAD | 42.34% |
| 2020 | 29.14 Million CAD | 9123.3% |
| 2019 | 315.99 Thousand CAD | 797.64% |
| 2018 | 35.2 Thousand CAD | -13.12% |
| 2017 | 40.52 Thousand CAD | -69.25% |
| 2016 | 131.75 Thousand CAD | -90.95% |
| 2015 | 1.45 Million CAD | 118.31% |
| 2014 | 666.87 Thousand CAD | 78.43% |
| 2013 | 373.73 Thousand CAD | -53.79% |
| 2012 | 808.76 Thousand CAD | 183.38% |
| 2011 | 285.4 Thousand CAD | 34.08% |
| 2010 | 212.85 Thousand CAD | 62.47% |
| 2009 | 131.01 Thousand CAD | 78.82% |
| 2008 | 73.26 Thousand CAD | 1293.46% |
| 2007 | 5258.00 CAD | -85.98% |
| 2006 | 37.5 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 18.94 Million CAD | 3.29% |
| 2023 Q3 | 18.13 Million CAD | 2.83% |
| 2023 Q4 | 18.33 Million CAD | 1.12% |
| 2023 Q1 | 16.45 Million CAD | -11.0% |
| 2023 FY | 18.33 Million CAD | -0.82% |
| 2023 Q2 | 17.63 Million CAD | 7.16% |
| 2022 Q2 | 21.6 Million CAD | -35.69% |
| 2022 Q4 | 18.49 Million CAD | -11.06% |
| 2022 Q3 | 20.79 Million CAD | -3.75% |
| 2022 FY | 18.49 Million CAD | -55.43% |
| 2022 Q1 | 33.58 Million CAD | -19.04% |
| 2021 FY | 41.48 Million CAD | 42.34% |
| 2021 Q1 | 19.94 Million CAD | -31.57% |
| 2021 Q3 | 22.66 Million CAD | 5.81% |
| 2021 Q4 | 41.48 Million CAD | 83.05% |
| 2021 Q2 | 21.41 Million CAD | 7.4% |
| 2020 Q3 | 16.69 Million CAD | -0.94% |
| 2020 FY | 29.14 Million CAD | 9123.3% |
| 2020 Q1 | 1 Million CAD | 216.7% |
| 2020 Q2 | 16.84 Million CAD | 1583.73% |
| 2020 Q4 | 29.14 Million CAD | 74.62% |
| 2019 Q4 | 315.99 Thousand CAD | 242.18% |
| 2019 Q2 | 71.12 Thousand CAD | 54.25% |
| 2019 Q3 | 92.34 Thousand CAD | 29.85% |
| 2019 Q1 | 46.1 Thousand CAD | 30.98% |
| 2019 FY | 315.99 Thousand CAD | 797.64% |
| 2018 Q3 | 107.64 Thousand CAD | 429.57% |
| 2018 Q2 | 20.32 Thousand CAD | -77.05% |
| 2018 Q1 | 88.56 Thousand CAD | 118.58% |
| 2018 FY | 35.2 Thousand CAD | -13.12% |
| 2018 Q4 | 35.2 Thousand CAD | -67.3% |
| 2017 Q1 | 195.02 Thousand CAD | 48.02% |
| 2017 Q3 | 203.02 Thousand CAD | 76.92% |
| 2017 Q4 | 40.52 Thousand CAD | -80.04% |
| 2017 Q2 | 114.75 Thousand CAD | -41.16% |
| 2017 FY | 40.52 Thousand CAD | -69.25% |
| 2016 Q4 | 131.75 Thousand CAD | -81.2% |
| 2016 FY | 131.75 Thousand CAD | -90.95% |
| 2016 Q1 | 1.39 Million CAD | -3.93% |
| 2016 Q2 | 1.53 Million CAD | 9.87% |
| 2016 Q3 | 700.88 Thousand CAD | -54.39% |
| 2015 Q4 | 1.45 Million CAD | 15.71% |
| 2015 Q2 | 1.02 Million CAD | 24.96% |
| 2015 Q1 | 820.16 Thousand CAD | 22.99% |
| 2015 FY | 1.45 Million CAD | 118.31% |
| 2015 Q3 | 1.25 Million CAD | 22.76% |
| 2014 Q3 | 530.95 Thousand CAD | 4.47% |
| 2014 Q1 | 254.05 Thousand CAD | -32.02% |
| 2014 FY | 666.87 Thousand CAD | 78.43% |
| 2014 Q2 | 508.23 Thousand CAD | 100.04% |
| 2014 Q4 | 666.87 Thousand CAD | 25.6% |
| 2013 Q4 | 373.73 Thousand CAD | 13.6% |
| 2013 FY | 373.73 Thousand CAD | -53.79% |
| 2013 Q3 | 328.98 Thousand CAD | 18.09% |
| 2013 Q2 | 278.6 Thousand CAD | -41.16% |
| 2013 Q1 | 473.49 Thousand CAD | -41.45% |
| 2012 Q3 | 245.12 Thousand CAD | 131.49% |
| 2012 FY | 808.76 Thousand CAD | 183.38% |
| 2012 Q2 | 105.88 Thousand CAD | -39.01% |
| 2012 Q4 | 808.76 Thousand CAD | 229.95% |
| 2012 Q1 | 173.61 Thousand CAD | -39.17% |
| 2011 Q2 | 82.93 Thousand CAD | -54.42% |
| 2011 Q1 | 181.95 Thousand CAD | -14.52% |
| 2011 FY | 285.4 Thousand CAD | 34.08% |
| 2011 Q4 | 285.4 Thousand CAD | -12.7% |
| 2011 Q3 | 326.92 Thousand CAD | 294.2% |
| 2010 FY | 212.85 Thousand CAD | 62.47% |
| 2010 Q3 | 72.1 Thousand CAD | -8.69% |
| 2010 Q2 | 78.96 Thousand CAD | -22.24% |
| 2010 Q1 | 101.55 Thousand CAD | -22.49% |
| 2010 Q4 | 212.85 Thousand CAD | 195.22% |
| 2009 Q3 | 131.58 Thousand CAD | 49.5% |
| 2009 Q2 | 88.01 Thousand CAD | 67.54% |
| 2009 Q1 | 52.53 Thousand CAD | -28.3% |
| 2009 FY | 131.01 Thousand CAD | 78.82% |
| 2009 Q4 | 131.01 Thousand CAD | -0.43% |
| 2008 Q1 | 18.01 Thousand CAD | 242.7% |
| 2008 Q2 | 15.46 Thousand CAD | -14.2% |
| 2008 FY | 73.26 Thousand CAD | 1293.46% |
| 2008 Q4 | 73.26 Thousand CAD | 259.92% |
| 2008 Q3 | 20.35 Thousand CAD | 31.68% |
| 2007 Q1 | 37.8 Thousand CAD | 0.8% |
| 2007 Q2 | 45 Thousand CAD | 19.06% |
| 2007 Q3 | 5118.00 CAD | -88.63% |
| 2007 Q4 | 5258.00 CAD | 2.74% |
| 2007 FY | 5258.00 CAD | -85.98% |
| 2006 FY | 37.5 Thousand CAD | 0.0% |
| 2006 Q4 | 37.5 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -408.308% |
| Arrayit Corporation | 7.49 Million USD | -144.641% |
| Atlantic International Corp. | 3.82 Million USD | -379.017% |
| Biocept, Inc. | 22.01 Million USD | 16.687% |
| Bioqual, Inc. | 18.93 Million USD | 3.159% |
| CardioGenics Holdings Inc | 1.79 Million USD | -921.756% |
| DermTech, Inc. | 64.75 Million USD | 71.678% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 97.505% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -48.069% |
| iMD Companies, Inc. | 1.67 Million USD | -995.422% |
| IDenta Corp. | 1.01 Million USD | -1710.155% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 34.866% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -6055.368% |
| InVitro International | 78.99 Thousand USD | -23117.793% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 7.042% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -14084.192% |
| Medical Imaging Corp. | 9.51 Million USD | -92.703% |
| NovelStem International Corp. | 4.2 Million USD | -336.029% |
| Optigenex Inc. | 9.57 Million USD | -91.625% |
| PharmChem, Inc. | 558.64 Thousand USD | -3182.884% |
| Proteome Sciences plc | 18.48 Million USD | 0.808% |
| Response Genetics, Inc | 15.86 Million USD | -15.584% |
| Rennova Health, Inc. | 49.66 Million USD | 63.075% |
| RushNet, Inc. | 6.23 Million USD | -193.953% |
| ScreenPro Security Inc. | 1.6 Million USD | -1045.813% |
| Stella Diagnostics Inc. | 18 Million USD | -1.857% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -123.547% |
| Todos Medical Ltd. | 50.15 Million USD | 63.435% |